Cabozantinib Plus Nivolumab Emerges as Preferred First-Line Treatment for Advanced Renal Cell Carcinoma

Oncologists treating patients with advanced renal cell carcinoma (RCC) are increasingly selecting cabozantinib plus nivolumab as their preferred first-line immunotherapy-tyrosine kinase inhibitor (TKI) combination, driven by superior tolerability profiles and flexible dosing options compared to other available regimens.

Treatment Selection Patterns Shift Toward Cabozantinib-Based Therapy

Multiple oncology experts report a notable shift in their prescribing patterns, moving away from earlier combinations toward cabozantinib plus nivolumab. Dr. Pallavi Jasti noted this evolution in practice: "Initially, I used axitinib plus pembrolizumab a lot because it was the first one on the market, but more recently, most of my patients are getting cabozantinib plus nivolumab."

This preference extends across different patient populations and risk categories. Dr. Alexander Barsouk explained his approach: "For me, I will probably use more cabozantinib upfront. I've been using it early and have had a good experience. I haven't had much concern when using cabozantinib in the second-line setting because there are strong data for it and it's associated with a good quality of life."

Tolerability Advantages Drive Clinical Decision-Making

The superior tolerability profile of cabozantinib plus nivolumab represents a key factor in treatment selection. Data from the CheckMate 9ER study revealed that approximately 10% of patients discontinued cabozantinib due to adverse events, with discontinuation due to nivolumab-associated adverse events also around 10% to 11%.

In contrast, lenvatinib plus pembrolizumab showed significantly higher discontinuation rates. The lenvatinib discontinuation rate reached 25.6%, and among patients starting at the mandated 20-mg dose of lenvatinib, 28% stopped pembrolizumab and 13% discontinued both agents, compared to less than 10% for those on cabozantinib plus nivolumab.

Dr. Shilpa Gupta emphasized this clinical reality: "I think this is everybody's clinical experience too, and I don't think anybody in the group said they don't see these challenges with lenvatinib/pembrolizumab."

Flexible Dosing Enhances Clinical Management

The ability to easily adjust cabozantinib dosing provides significant clinical advantages. Dr. Rana McKay detailed the practical benefits: "It's very easy to titrate cabozantinib, drop them down to 20 mg daily or 20 mg every other day. Sometimes you can even adjust the dose on days of the week. I have some patients who receive 40 mg 3 times a week, 20 mg the remaining days of the week."

This flexibility contrasts with lenvatinib's more complex dosing structure. Patients typically start at 20 mg, with almost 70% requiring dose reductions, dropping sequentially from 20 mg to 14 mg to 10 mg to 8 mg, often requiring new pill packs and creating potential management difficulties.

Efficacy Across Risk Groups and Special Populations

The combination demonstrates effectiveness across different risk categories and patient populations. For patients with brain metastases, a particularly challenging population, Dr. Robert Yoo noted: "Cabozantinib/nivolumab seems to be the go-to choice because there are more data for brain metastases."

However, treatment selection remains individualized based on patient characteristics. Dr. Baidehi Maiti described her approach: "For patients with symptomatic high disease burden, especially if they have liver metastases, I probably lean towards lenvatinib/pembrolizumab, but that will probably be the only situation. Otherwise, I would pick cabozantinib/nivolumab."

Quality of Life and Response Considerations

Clinical experts report that cabozantinib plus nivolumab offers better quality of life compared to other combinations, with manageable adverse event profiles and robust response rates. The regimen also demonstrates low primary progressive disease rates, making it suitable for patients across risk categories.

Dr. Darshil Shah provided perspective on the overall landscape: "Looking at the data, cabozantinib/nivolumab seems to be the go-to for all risk types, but in my experience axitinib plus pembrolizumab is better tolerated. All 3 treatments are category 1. Patient characteristics matter, but for patients with intermediate to poor risk, I would prefer cabozantinib/nivolumab."

Survival Benefits and Long-term Outcomes

The immunotherapy component of these combinations provides significant survival benefits, particularly in intermediate- and poor-risk patients. Dr. Aneel Chowdhary explained: "There's a significant survival benefit with these combinations, especially in intermediate- and poor-risk patients, but the reason we're losing that benefit is because of the immunotherapy, in my opinion."

Long-term follow-up data continues to support the use of immunotherapy-TKI combinations, with progression-free survival and median duration of response representing important parameters demonstrating the continued effectiveness of these regimens.

The evolving treatment landscape for advanced RCC reflects a maturation in clinical experience with immunotherapy-TKI combinations, with cabozantinib plus nivolumab emerging as a preferred option based on its favorable balance of efficacy, tolerability, and clinical manageability.